|
翁比他韦市场分析报告
|
Hepatitis C Virus (HCV) - Market Insights, Epidemiology, and Market Forecast - 2030 ... (PI). Harvoni (ledipasvir/sofosbuvir), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets ... (ledipasvir and sofosbuvir), Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir ...
Hepatitis C: KOL Insight ... ) Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta) Zepatier (elbasvir ...
Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023 Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that ...
NPS+ Hepatitis C Virus (HCV) Infection US [2018] ... ) Sovaldi (sofosbuvir; Gilead) Viekira Pak (ombitasvir/paritaprevir/ritonavir; AbbVie) Zepatier (elbasvir ...
NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018] ... Cilag) Sovaldi (sofosbuvir; Gilead) Viekirax (ombitasvir/paritaprevir/ritonavir; AbbVie) Zepatier (elbasvir ...
Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019 ... or RG7128 7. Sunvepra (Asunaprevir) 8. ABT-450/r + Ombitasvir (ABT-267) + Dasabuvir (ABT-333 ...
Hepatitis C: Update Bulletin [February 2016] ... KOLs think of AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged ... concerns about AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged ...
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni? ... AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir ...
|
|
|